Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Stara Tura – page 14

273 clinical trials in Stara Tura, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Stara Tura at a glance
273
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

273 trials in Stara Tura

Open in trial search

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:SlovakiaSlovakia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Axial Spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Rheumatoid arthritis

Not recruiting

Study of LY3871801 for Adults with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:LY3871801
  • Sponsor:Eli Lilly & Co.

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Iodide
  • Sponsor:Faraday Pharmaceuticals Inc.

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Tendon disorder

Not recruiting

Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Stara Tura

What the registry says about research in the country

01 Cardiovascular Diseases

In Stara Tura, Slovakia, clinical research is centered on Cardiovascular Diseases, with two actively recruiting trials aimed at improving outcomes for patients with a range of heart‑related conditions.

  • Evaluation of a novel oral agent aimed at lowering the incidence of major cardiovascular events
  • Investigation of an RNA‑based therapy designed to control hypertension and reduce cardiovascular mortality
  • Inclusion of participants with atherosclerotic disease, chronic kidney disease, established cardiovascular disease, high cardiovascular risk, or hypertension
  • Focus on key endpoints such as cardiovascular death, non‑fatal myocardial infarction, non‑fatal stroke, and heart‑failure hospitalization

Both studies are led by a single investigator and, despite the city’s modest research infrastructure, strive to generate evidence that could influence treatment guidelines across Europe.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.